Trials / Completed
CompletedNCT02002208
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
A Study of the Effect of OC000459 on Signs and Symptoms in Subjects With Moderate to Severe Atopic Dermatitis: A Randomised Double Blind Placebo Controlled Parallel Group Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 142 (actual)
- Sponsor
- Atopix Therapeutics, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 48 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
Detailed description
The study will include patients with a Th2 high eosinophilic phenotype who typically have more severe disease and are prone to flare.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OC000459 | Oral CRTH2 antagonist |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-09-01
- Completion
- 2016-02-01
- First posted
- 2013-12-05
- Last updated
- 2018-03-26
- Results posted
- 2016-12-08
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02002208. Inclusion in this directory is not an endorsement.